gavo-cel
Phase 2- Indications
- Ovarian cancer, Mesothelioma
Company intelligence / Profile preview
TCR2 Therapeutics Inc.
Cambridge, Massachusetts, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
TCR2 Therapeutics demonstrated clinical activity with its lead program gavo-cel in multiple treatment-refractory mesothelin-expressing solid tumor indications. In Phase 1, tumor regression was observed in 93% of patients when used as monotherapy, with partial responses in all indications treated.
- Therapeutic areas
- OncologyImmunology
- Modalities
- T cell therapiesCell therapyTRuC-T cells
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Arbor Biotechnologies
Beyond the preview
Go deeper on TCR2 Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCR2 Therapeutics Inc..